Natera, Inc. (NTRA) Down 11.2% — Do I Sell Before It Slides Further?
Key Points
Natera, Inc. (NTRA) plummeted in the latest session, sliding 11.22% and shedding $24.68 to trade at $195.14. The selloff places the stock well below its 52-week high of $256.36, a level that now sits more than 23% above the current price. That distance from the recent peak underscores how much ground NTRA has lost in a relatively short window, though the stock remains comfortably above its 52-week low of $131.81.
Volume is telling a stark story of its own. Shares changed hands at 2,351,737 on the session, nearly double the 90-day average of 1,228,366 — a surge that signals broad-based participation in today's decline rather than a thin, low-conviction retreat. When selling pressure coincides with volume running at nearly twice the rolling average, it points to active distribution rather than routine profit-taking. The elevated turnover adds weight to the price action, suggesting the move reflects meaningful selling interest across the shareholder base rather than an isolated, low-participation dip.
Why Natera, Inc. Price is Moving Lower
Natera, Inc. (NTRA) shares came under sharp pressure on May 8, 2026, following the release of mixed first-quarter results the prior evening. While revenue of $696.6 million represented a strong 38.8% year-over-year gain and the company raised its full-year guidance to $2.74 billion–$2.82 billion, the earnings-per-share result of -$0.60 missed analyst estimates of -$0.53, delivering a shortfall that rattled confidence. Adding to the negative sentiment, a series of insider sales disclosed between May 1 and May 5 — including transactions by the CEO and CFO totaling over $186,000 — amplified concern that insiders may be taking profits near elevated price levels. That combination of an EPS miss and insider activity proved difficult to overlook, even against an otherwise constructive operational backdrop.
The profit picture remains a persistent headwind. Natera carries a trailing profit margin of -9.02% and posted a net loss of $85.1 million in Q1 2026 alone, meaning the company continues to consume capital despite accelerating revenue. Quarter-over-quarter revenue growth of 12.4% and oncology segment expansion of 54% demonstrate operational momentum, but investors appear increasingly focused on the path to profitability — and the Q1 results did little to clarify that timeline.
Caution is warranted given the positioning with in the Health Care sector as well. Several of Natera's industry peers, including BeOne Medicines AG (ONC) and Revolution Medicines, Inc. (RVMD), carry weak Weiss Ratings, reflecting broader challenges facing growth-stage biotech companies that prioritize expansion over near-term earnings. For NTRA, the gap between revenue strength and bottom-line delivery remains the central pressure point driving today's selloff.
What is the Natera, Inc. Rating - Should I Sell?
Weiss Ratings assigns NTRA a D rating, with a current recommendation of Sell. Despite the last upgrade, the stock remains firmly in Sell territory, and the underlying data makes clear why investors should approach Natera with caution. Strong revenue momentum has not been enough to overcome structural profitability problems and weak capital efficiency.
Revenue expanding at nearly 40% annually earns the Good Growth Index, one of the few genuine bright spots in Natera's profile. But growth without profit is a treadmill, and a -9.02% profit margin paired with a forward P/E of -143.36 tells the real story. Return on assets, return on equity, and return on invested capital are all deeply negative — figures that produce the Very Weak Efficiency Index and signal that every dollar Natera deploys is generating losses rather than value. For shareholders, that inefficiency has a direct cost.
Price performance has been inconsistent enough to earn only the Fair Total Return Index, and stock price swings that leave little room for investor comfort earn the Fair Volatility Index. Taken together, these two readings mean NTRA carries meaningful downside exposure without a reliable track record of compensating shareholders for that risk. The Excellent Solvency Index, driven by a strong cash and liquidity position, does reduce the near-term threat of financial distress — but liquidity alone does not fix a business that continues to burn through capital unprofitably.
Natera is not alone in its struggles within Health Care sector. Zoetis Inc. (ZTS, D+), BeOne Medicines AG (ONC, D-), and BioNTech SE (BNTX, D-) all carry Sell ratings, reflecting broader sector-wide pressure. Among these peers, NTRA's combination of hypergrowth and persistent losses keeps it in a precarious position that the current D rating accurately reflects.
About Natera, Inc.
Natera, Inc. (NTRA) is a diagnostics company headquartered in Austin, Texas, focused on the development and commercialization of molecular testing services across multiple clinical areas. Founded in 2003 and originally operating as Gene Security Network, LLC, the company rebranded to its current name in 2012 and is now listed on the NASDAQ exchange. Natera operates within the Health Care sector, competing in the Pharmaceuticals, Biotechnology and Life Sciences industry alongside a broad range of genetic testing and diagnostics providers worldwide.
The company's product portfolio spans oncology, women's health, and organ health. In oncology, Natera offers Signatera, a personalized circulating tumor DNA blood test used for minimal residual disease assessment and treatment response evaluation, alongside Latitude for colorectal cancer, Altera for comprehensive genomic profiling, and Empower for hereditary cancer screening. Its women's health lineup includes Panorama, a non-invasive prenatal test; Horizon, a carrier screening product; and Fetal Focus and Vistara, both single-gene NIPT solutions screening for multiple inherited conditions. Anora addresses pregnancy loss by analyzing miscarriage tissue. On the organ health side, Prospera evaluates active rejection risk in solid organ transplant patients, while Renasight provides a kidney-focused gene panel test.
Natera distributes its services through a direct sales force and laboratory distribution partners, serving independent laboratories, medical centers, physician practices, and pharmaceutical companies. The company also licenses its cloud-based Constellation software platform to expand its reach. A partnership with BGI Genomics Co., Ltd. supports the development and commercialization of next-generation sequencing-based assays for clinical use globally.
Investor Outlook
With Natera, Inc. (NTRA) carrying a D (Sell) rating, investors should exercise caution and closely monitor whether the company can translate its revenue momentum into sustainable profitability and improved risk-adjusted returns. Watch for developments in Health Care sector trends, margin improvement, and any shifts in the underlying metrics that drive the overall rating before reassessing the stock's position in a portfolio. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--